Inventor · disambiguated record
Ningshu Liu
Also filed as: LIU NINGSHU
19 granted patents·16 pending applications·61 citations·filing 1998–2023
92Inventor score
Top patents by PatentIndex Score
35 records- 0182US10117874B2Combination of PI3K-inhibitorsBayer Pharma AG·Filed 2014·Granted Nov 6, 2018·6 cites·14 claims
- 0280US9999623B2Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomasBayer Pharma AG·Filed 2014·Granted Jun 19, 2018·6 cites·3 claims
- 0379US10226469B2Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomasBayer Pharma AG·Filed 2018·Granted Mar 12, 2019·3 cites·8 claims
- 0478US10383877B2Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myelomaBAYER IP GMBH·Filed 2014·Granted Aug 20, 2019·3 cites·3 claims
- 0575US10406162B2Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinationsBayer Pharma AG·Filed 2016·Granted Sep 10, 2019·3 cites·13 claims
- 0675US9278925B2Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-oneLIU NINGSHU·Filed 2012·Granted Mar 8, 2016·3 cites·8 claims
- 0773US9000026B2Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapyLIU NINGSHU·Filed 2012·Granted Apr 7, 2015·2 cites·7 claims
- 0872US10202385B2Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolinesLIU NINGSHU·Filed 2012·Granted Feb 12, 2019·5 cites·7 claims
- 0970US8895549B2Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisSCOTT WILLIAM JOHNSTON·Filed 2011·Granted Nov 25, 2014·2 cites·15 claims
- 1067US8957064B2Fused pyrimidinesVENNEMANN MATTHIAS·Filed 2010·Granted Feb 17, 2015·3 cites·13 claims
- 1165US10124007B2Combination of PI3K-inhibitorsBayer Pharma AG·Filed 2014·Granted Nov 13, 2018·0 cites·8 claims
- 1265US6380170B1Nucleic acid construct for the cell cycle regulated expression of structural genesAVENTIS PHARMA GMBH·Filed 1998·Granted Apr 30, 2002·25 cites·16 claims
- 1364US2024382495A1Combinations of copanlisib with anti-pd-1 antibodyBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1460US2011251191A1Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myelomaBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 1555US11684672B2Combinations of copanlisib with anti-PD-1 antibodyBayer Pharma AG·Filed 2018·Granted Jun 27, 2023·0 cites·34 claims
- 1654US9212140B2(5s,8s)-3-(4′-chlor-3′-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one (compound A) for treatmentLIU NINGSHU·Filed 2012·Granted Dec 15, 2015·0 cites·2 claims
- 1753US9902727B2Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisBAYER IP GMBH·Filed 2014·Granted Feb 27, 2018·0 cites·15 claims
- 1852US2021369724A1Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compoundsBAYER AG·Filed 2019·Application pending·0 cites
- 1942US10130633B2CompoundsBayer Pharma AG·Filed 2014·Granted Nov 20, 2018·0 cites·17 claims
- 2042US2016052898A1Novel compoundsBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2140US2018148418A1Amido-substituted cyclohexane derivativesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 2239US2004029247A1Regulation of human adenylate cyclase, type ivFiled 2001·Application pending·0 cites
- 2337US2013040935A1Cyclic keto-enols for therapyBAYER IP GMBH·Filed 2011·Application pending·0 cites
- 2437US2013310362A1Fused pyrimidinesBECKERS BARBARA·Filed 2010·Application pending·0 cites
- 2536US9730943B2Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolinesSCOTT WILLIAM JOHNSTON·Filed 2011·Granted Aug 15, 2017·0 cites·5 claims
- 2636US9675616B2Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolinesSCOTT WILLIAM JOHNSTON·Filed 2011·Granted Jun 13, 2017·0 cites·11 claims
- 2736US2012129833A1Cyclic ketoenols for therapyLIU NINGSHU·Filed 2011·Application pending·0 cites
- 2836US2013184270A1Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinationsLIU NINGSHU·Filed 2011·Application pending·0 cites
- 2933US2018044306A11,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitors of the wnt signalling pathwayBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3033US2018042931A1N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathwaysBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3133US2018028507A13-carbamoylphenyl-4-carboxamide and isophtalamide derivatives as inhibitors of the wnt signalling pathwayBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3231US2018042929A1Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolinesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 3331US2017107212A1Novel compoundsBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3431US2017114070A1Inhibitors of the wnt signalling pathwaysBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3530US9884063B2Amido-substituted azole compoundsBayer Pharma AG·Filed 2015·Granted Feb 6, 2018·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Ningshu Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →